Cardiovascular risk factors associated with antiretroviral therapy;Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue SUPPL. 1, 2009, Pages 24-32

  Pérez Camacho, Inés ^a   Camacho, Ángela ^b   Torre Cisneros, Julián ^b   Rivero, Antonio ^b  

^a HOSPITAL DE PONIENTE   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Abacavir; Cardiovascular risk; Highly active antiretroviral therapy (HAART); HIV

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK REDUCTION; SILENT MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DISEASE SUSCEPTIBILITY; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 76749122722     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(09)73442-1     Document Type: Article

References (100)

1. Lima V.D., Hogg R.S., Harrigan P.R., Moore D., Yip B., Wood E., et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21 (2007) 685-692
2. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
3. Mocroft A., Ledergerber B., Katlama C., Kirk O., Reiss P., D'Arminio Monforte A., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362 (2003) 22-29
4. Manfredi R., Sabbatani S., and Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. Coll Antropol 30 (2006) 479-488
5. Wong M.D., Shapiro M.F., Boscardin W.J., and Ettner S.L. Contribution of major diseases to disparities in mortality. N Engl J Med 347 (2002) 1585-1592
6. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-146
7. Aberg J.A. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 50 (2009) 54-64
8. Friis-Moller N., Sabin C.A., Weber R., D'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
9. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 (1999) 512-517
10. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
11. Bozzette S., Ake C., Tam H., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
12. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 Suppl (1998) F51-58
13. Dube M., and Sattler F. Metabolic complications of antiretroviral therapies. AIDS Clin Care 10 (1998) 41-44
14. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 98 (1998) 829-830
15. Gallet B., Pulik M., Genet P., Chedin P., and Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1958-1959
16. Henry K., Melroe H., Huebsch J., Hermundson J., Levine C., Swensen L., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351 (1998) 1328
17. Klein D., Hurley L.B., Quesenberry Jr. C.P., and Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 30 (2002) 471-477
18. Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D., and Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
19. Currier J., Taylor A., Boyd F., Dezii C.M., Kawabata H., Burtcel B., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33 (2003) 506-512
20. Kaplan R.C., Kingsley L.A., Sharrett A.R., Li X., Lazar J., Tien P.C., et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 44 (2007) 1074-1081
21. Obel N., Thompsen H.F., Kronborg G., Larsen C.S., Hildebrandt P.R., Sorensen H.T., et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population- based cohort study. Clin Infect Dis 44 (2007) 1625-1631
22. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., Wood K.C., et al., HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
23. Vaughn G., and Detels R. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohorte. AIDS Care 19 (2007) 492-499
24. Friis-Moller N., Sabin C., Weber R., D'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
25. Vaughn G., and Detels R. Protease inhibitors and cardiovascular disease: análisis of the Los Angeles County adult spectrum of disease cohorte. AIDS Care 19 (2007) 492-499
26. Stein J.H. Cardiovascular risks of antiretroviral therapy. N Engl J Med 356 (2007) 1773-1775
27. Purnell J.Q., Zambon A., Knopp R.H., Pizzuti D.J., Achari R., Leonard J.M., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14 (2000) 51-57
28. Periard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100 (1999) 700-705
29. Roberts A.D., Muesing R.A., Parenti D.M., Hsia J., Wasserman A.G., and Simon G.L. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 29 (1999) 441-443
30. Mulligan K., Grunfeld C., Tai V.W., Algren H., Pang M., Chernoff D.N., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23 (2000) 35-43
31. Noor M.A., Lo J.C., Mulligan K., Schwarz J.M., Halvorsen R.A., Schambelan M., et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15 (2001) F11-F18
32. Squires K., Lazzarin A., Gatell J.M., Powderly W.G., Pokrovskiy V., Delfraissy J.F., et al. Comparison of once-daily atazanavir to efavirenz each in combination with fixeddose zidovudina and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36 (2004) 1011-1019
33. Malan D.RN., Krantz E., David N., Wirtz V., Hammond J., McGrath D., and 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 47 (2008) 161-167
34. Smith K.Y., Weinberg W.G., Dejesus E., Fischl M.A., Liao Q., Ross L., et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 5 (2008) 5
35. Eron Jr. J., Yeni P., Gathe Jr. J., Estrada V., DeJesus E., Staszewski S., et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368 (2006) 476-482
36. Molina J.M., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N., et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372 (2008) 646-655
37. Ortiz R., Dejesus E., Khanlou H., Voronin E., Van Lunzen J., Andrade-Villanueva J., et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22 (2008) 1389-1397
38. Walmsley S., Avihingsanon A., Slim J., Ward D.J., Ruxrungtham K., Brunetta J., et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 50 (2009) 367-374
39. Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, De Wit S, et al. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11,Montreal. Abstract 44LB.
40. Shikuma C.M., Yang Y., Glesby M.J., Meyer III W.A., Tashima K.T., Ribaudo H.J., et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 44 (2007) 540-550
41. Haubrich R, Riddler S, DiRienzo G, L Komarow l, W Powderly W, Garren K, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized phase III trial of NRTI-, PI-, and NNRTIsparing regimens for initial treatment of HIV-1. Presented at: 14th Conference on Retroviruses and Opportunistic Infections (CROI); 2007; Los Angeles, CA. Abstract.
42. Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi, F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 PLoS Med. 2004;1:e19.
43. Kumar P.N., Rodriguez-French A., Thompson M.A., Tashima K.T., Averitt D., Wannamaker P.G., et al. A prospective, 96-week study of the impact of Trizivir, Combivir/ nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 7 (2006) 85-98
44. Sabin C.A., Worm S.W., Weber R., Reiss P., El-Sadr W., Dabis F., et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008) 1417-1426
45. Benson C, Ribaudo H, Zheng E, Koletar S, Smurzynski M, Bosch R, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11 2009, Montreal, Canada. Abstract 721.
46. Reiss P. Abacavir and Cardiovascular Risk. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11 2009, Montreal, Canada. Abstract 152.
47. Cooper D, Bloch M, Humphries A, Amin J, Baker D, Emery S, for the STEAL Study Investigators. Simplification with Fixed-dose Tenofovir/Emtricitabine or Abacavir/ Lamivudine in Adults with Suppressed HIV Replication: The STEAL Study, a Randomized, Open-label, 96-Week, Non-inferiority Trial. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11 2009, Montreal, Canada. Abstract 576.
48. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections February 8-11 2009, Montreal, Canada. Abstract 43LB.
49. Hsue P, Wu Y, Schnell A, Ganz P, Hunt P, Hatano H, et al. Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11 2009, Montreal, Canada. Abstract 723.
50. Satchell C, O'Connor E, Peace A, Cotter A, Sheehan G, Tedesco T, et al. Platelet hyper- reactivity in HIV-1-infected patients on abacavir-containing ART. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11 2009, Montreal, Canada. Abstract 151LB.
51. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 (2001) 130-139
52. Dubé M.P., Stein J.H., Aberg J.A., Fichtenbaum C.J., Gerber J.G., Tashima K.T., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 (2003) 613-627
53. Liang J.S., Distler O., Cooper D.A., Jamil H., Deckelbaum R.J., Ginsberg H.N., et al. HIV protease inhibitors Project apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7 (2001) 1327-1331
54. Sankatsing R.R., Wit F.W., Pakker N., Vyankandondera J., Mmiro F., Okong P., et al. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 196 (2007) 15-22
55. Lazzaretti R, Pinto-Ribeiro J, Kummer R, Polanczyk C, Sprinz E. Dietary intervention when starting HAART prevents the increase in lipids independently of drug regimen: a randomized trial. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEAB303.
56. Meigs J.B., Rutter M.K., Sullivan L.M., Fox C.S., D'Agostino Sr. R.B., and Wilson P.W. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 30 (2007) 1219-1225
57. Wollesen F., Berglund L., and Berne C. Insulin resistance and atherosclerosis in diabetes mellitus. Metabolism 51 (2002) 941-948
58. Dube M.P., Sprecher D., Henry W.K., Aberg J.A., Torriani F.J., Hodis H.N., et al. Preliminare guidelines for the evaluation and management of dyslipemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis 31 (2000) 1216-1224
59. Hadigan C., Corcoran C., Stanley T., Piecuch S., Klibanski A., and Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition gonadal function, and proteasa inhbitor use. J Clin Endocrinol Metab 85 (2000) 35-41
60. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., and Capeau J. The HIV proteasa inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50 (2001) 1378-1388
61. Nolte L., Yarasheski K.E., Kawanaka K., Fisher J., Le N., and Holloszy J.O. The HIV protease inhibitor indinavir decreases insulin-and coraction-stimulated glucose transport in skeletal muscle. Diabetes 50 (2001) 1397-1401
62. Murata H., Hruz P.W., and Mueckler M. The mechanism of insulin resistance caused by HIV proteasa inhibitor therapy. J Biol Chem 27 (2000) 20251-20354
63. Andersen O., Haugaard S.B., Andersen U.B., Friis-Møller N., Storgaard H., Vølund A., et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 52 (2003) 1343-1353
64. Behrens G.M., Boerner A.R., Weber K., Van den Hoff J., Ockenga J., Brabant G., et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110 (2002) 1319-1327
65. Lenhard J.M., Furfine E.S., Jain R.J., Ittoop O., Orband-Miller L.A., Blanchard S.G., et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 47 (2000) 121-129
66. Man Z.V., Hirashima T., Mori S., and Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushima fatty rats, a non-insulin-dependent diabetes model. Metabolism 49 (2000) 108-114
67. Ledru E., Christeff N., Patey O., De Truchis P., Melchior J.C., and Gougeon M.L. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95 (2000) 3191-3198
68. Kotler D.P. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 49 Suppl 2 (2008) S79-85
69. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., and Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999) 2093-2099
70. Wohl D.A., McComsey G., Tebas P., Brown T.T., Glesby M.J., and Reeds D. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43 (2006) 645-653
71. Mulligan K., Tai V.W., Algren H., Abrams D.I., Leiser R.J., Lo J.C., et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 26 (2001) 443-448
72. Mallal S.A., John M., Moore C.B., James I.R., and McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14 (2000) 1309-1316
73. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
74. Casula M., Van der Valk M., Wit F.W., Nievaard M.A., and Reiss P. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition. HIV Med 8 (2007) 32-37
75. Lagathu C., Bastard J.P., Auclair M., Maachi M., Kornprobst M., Capeau J., et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 9 (2004) 911-920
76. Mallon P.WG., Unemori P., Sedwell R., Morey A., Rafferty M., Williams K., et al. In vivo, nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of mitochondrial DNA depletion. J Infect Dis 191 (2005) 1686-1696
77. Grundy S.M., Brewer H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
78. Bonfanti P., Giannattasio C., Ricci E., Facchetti R., Rosella E., Franzetti M., et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 45 (2007) 426-431
79. Samaras K., Wand H., Law M., Emery S., Cooper D., and Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30 (2007) 113-119
80. Jacobson D.L., Tang A.M., Spiegelman D., Thomas A.M., Skinner S., Gorbach S.L., et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43 (2006) 458-466
81. Palacios R., Santos J., González M., Ruiz J., and Márquez M. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS 18 (2007) 184-187
82. Wand H., Calmy A., Carey D.L., Samaras K., Carr A., Law M.G., et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infection. AIDS 21 (2007) 2445-2453
83. Mangili A., Jacobson D.L., Gerrior J., Polak J.F., Gorbach S.L., and Wanke C.A. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 44 (2007) 1368-1374
84. Hsue P.Y., Hunt P.W., Sinclair E., Bredt B., Franklin A., Killian M., et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirusspecific T-cell responses. AIDS 20 (2006) 2275-2283
85. Lau B., Sharrett A.R., Kingsley L.A., Post W., Palella F.J., Visscher B., et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 166 (2006) 64-70
86. Sitia G., De Bona A., Bagaglio S., Galli L., Paties C.T., Uberti-Foppa C., et al. Naive HIV/ HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy. Antivir Ther 11 (2006) 385-389
87. Mynarcik D.C., McNurlan M.A., Steigbigel R.T., Fuhrer J., Gelato M.C., et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25 (2000) 312-321
88. Kuller L and the SMART Study Group. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, M.A.
89. Strategies for Management of Anti-Retroviral Therapy/INSIGHT and DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22 (2008) F17-24
90. Stein J.H., Klein M.A., Bellehumeur J.L., McBride P.E., Wiebe D.A., Otvos J.D., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104 (2001) 257-262
91. Nolan D., Watts G.F., Herrmann S.E., French M.A., John M., and Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect CV risk?. QJM 96 (2003) 825-832
92. Murphy L, Zala C, Berzins B, Fichtenbaum C, Dube M, Guaraldi G, et al. Endothelial function, lipoproteins, and cardiovascular inflammatory markers in treated HIV-infected patients with hyperlipidemia who were switched to an atazanavirwith atazanavir-containing regimen or continued on other protease inhibitor inhibitor-based therapy: switch to atazanavir brachial artery reactivity study. 16th Conference on Retroviruses and Opportunistic Infections February 8-11 2009, Montreal, Canada. Abstract 722LB.
93. Conklin B., Fu W., Lin P., Lundsen A., Yao Q., and Chen C. HIV protease inhibitor ritonavir induces endothelial dysfunction in porcine arteries. J Surg Res 114 (2003) 249
94. Shankar S.S., Dubé M.P., Gorski J.C., Klaunig J.E., and Steinberg H.O. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 150 (2005) 933
95. Seminari E., Pan A., Voltini G., Carnevale G., Maserati R., Minoli L., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162 (2002) 433-438
96. Hsue P.Y., Lo J.C., Franklin A., Bolger A.F., Martin J.N., Deeks S.G., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109 (2004) 1603-1608
97. Duong M., Cottin Y., Piroth L., Fargeot A., Lhuiller I., Bobillier M., et al. Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 34 (2002) 523-528
98. Shaw L.J., Raggi P., Berman D.S., and Callister T.Q. Cost effectiveness of screening for CV disease with measures of coronary calcium. Prog Cardiovasc Dis 46 (2003) 171-184
99. Kingsley L.A., Cuervo-Rojas J., Muñoz A., Palella F.J., Post W., Witt M.D., et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 22 (2008) 1589-1599
100. Acevedo M., Sprecher D.L., Calabrese L., Pearce G.L., Coyner D.L., Halliburton S.S., et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for CV prevention'. Atherosclerosis 163 (2002) 349-354